| 1 |
Editorial O. New perspectives in multidisciplinary treatment of esophageal cancer: the "first east asian conference on multidisciplinary treatment of esophageal cancer" held in chengdu, sichuan province[J]. J Thorac Dis, 2018, 10(5): 400-408.
|
| 2 |
Collaborators GBDOC. The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Gastroenterol Hepatol, 2020, 5(6): 582-597.
|
| 3 |
Chen R, Zheng RS, Zhang SW, et al. Analysis of incidence and mortality of esophageal cancer in China, 2015[J]. Zhonghua Yu Fang Yi Xue Za Zhi, 2019, 53(11): 1094-1097.
|
| 4 |
Shirakawa Y, Noma K, Maeda N, et al. Microanatomy-based standardization of left upper mediastinal lymph node dissection in thoracoscopic esophagectomy in the prone position[J]. Surg Endosc, 2020. DOI: 10.1007/s00464-020-07407-9. |
| 5 |
Shapiro J, Lanschot JJB, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015, 16(9): 1090-1098.
|
| 6 |
Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase iii multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018, 36(27): 2796-2803.
|
| 7 |
Wong IYH, Lam KO, Chan W, et al. Real-world scenario: cross regimen as preoperative therapy for oesophageal squamous cell carcinoma[J]. J Gastrointest Surg, 2020, 24(9): 1937-1947.
|
| 8 |
Wong IYH, Lam KO, Zhang RQ, et al. Neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil (PF) versus carboplatin and paclitaxel (CROSS Regimen) for esophageal squamous cell carcinoma (ESCC): a propensity score-matched study[J]. Ann Surg, 2020. DOI： 10.1097/SLA.0000000000004329. |
| 9 |
Leng X, He W, Yang H, et al. Prognostic impact of postoperative lymph node metastases after neoadjuvant chemoradiotherapy for locally advanced squamous cell carcinoma of esophagus: from the results of NEOCRTEC5010, a randomized multicenter study[J]. Ann Surg, 2019. DOI： 10.1097/SLA.0000000000003727. |
| 10 |
Yan W, Zhao P, Fu H, et al. Survival after induction chemotherapy and esophagectomy is not improved by adjuvant chemotherapy[J]. Ann Thorac Surg, 2019, 108(5): 1505-1513.
|
| 11 |
Xu J, Zheng B, Zhang S, et al. The clinical significance of the intraoperative pathological examination of bilateral recurrent laryngeal nerve lymph nodes using frozen sections in cervical field lymph node dissection of thoracic esophageal squamous cell carcinoma[J]. J Thorac Dis, 2019, 11(8): 3525-3533.
|
| 12 |
Mariette C, Piessen G, Briez N, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent[J]. Ann Surg, 2008, 247(2): 365-371.
|
| 13 |
Shirakawa Y, Noma K, Maeda N, et al.Standardization of bilateral upper mediastinal lymph node dissection using microanatomical concepts in minimally invasive esophagectomy[J]. Mini-invasive Surgery，2020，4(6):33. DOI: 10.20517/2574-1225.2020.30. |